ALKS 5461: Phase III data

Top-line data from the double-blind, North American Phase III FORWARD-1 trial in 66 MDD patients who had an inadequate response to antidepressant therapy,

Read the full 232 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE